Comparing the current results to its competitors, 10x Genomics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -12.23 %, despite the revenue increase by the most of its competitors of 8.66 %, recorded in the same quarter.
10x Genomics Inc 's Comment on Competition and Industry Peers
The life sciences industry includes both established and early-stage companies offering products in genomics analysis, single cell analysis, spatial analysis, and in situ analysis. Several companies are designing, manufacturing, and marketing products to compete in these areas. Some competitors possess greater financial resources, larger research and development teams, and more established marketing, distribution, service, and sales organizations, along with higher name recognition. Other competitors are developing novel technologies that may compete with or replace existing products. The company anticipates continued emergence of new competitors and increased competition intensity. The company identifies its differentiation based on product capabilities and performance, proprietary technologies protected by intellectual property, product development processes, scalable infrastructure, customer experience, and multidisciplinary teams.
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Standard Biotools Inc operates as a biotechnology company that specializes in the development and distribution of standard laboratory tools and reagents. They offer a diverse range of high-quality products including lab equipment, molecular diagnostics, and research reagents to meet the needs of scientists and researchers in the life sciences industry. With a customer-centric approach, Standard Biotools aims to provide reliable and affordable solutions to support advancements in scientific research and discovery.
Mettler toledo International Inc Share Performance
+12.29%
This Quarter
Mettler toledo International Inc
Profile
Mettler Toledo International Inc. operates on a business model that focuses on providing high-quality precision instruments and solutions tailored for various industries, including pharmaceuticals, food production, and laboratory research. The company emphasizes innovation and customer-centric service, delivering advanced technology and software alongside its instruments to enhance operational efficiency and accuracy. Additionally, Mettler Toledo generates recurring revenue through maintenance services, calibration, and consumables associated with its products, fostering long-term relationships with its clients.
Nautilus Biotechnology Inc's business model focuses on using advanced genomics and proteomics technologies to analyze and understand the human proteome.
Sources:
10x Genomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 10x Genomics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
